title: Standards of care for adults with convulsive status epilepticus: Belgian consensus recommendations.
abstract: Status epilepticus (SE) is a significant health problem, affecting approximately 1,000 to 4,000 individuals per year in Belgium. A workshop was convened by a panel of neurologists from major Belgian centers to review the latest information relating to the definition, diagnosis and treatment of convulsive SE. The panelists sought to make recommendations for practising neurologists, but also primary care physicians and physicians in intensive care units when initiating emergency measures for patients with convulsive SE. As there is an association between prolonged seizures and a poor outcome, the importance of early (within the first 5 minutes of seizure onset) and aggressive treatment is to be stressed. In addition to general systemic support (airway, circulation), intravenous administration of the benzodiazepines lorazepam or diazepam is recommended as first-line therapy. Intramuscular midazolam may also be used. If SE persists, second-line drugs include phenytoin or valproate, and third-line drugs the barbiturate phenobarbital, the benzodiazepine midazolam, or the anaesthetics thiopental or propofol, or eventually ketamine. If the patient does not recover after therapy, monitoring of seizures should involve an electroencephalogram to avoid overlooking persistence of clinically silent SE. As a general rule, the intensity of the treatment should reflect the risk to the patient from SE, and drugs likely to depress respiration and blood pressure should initially be avoided. If initial treatment with a benzodiazepine fails to control seizures, the patient must be referred to the emergency unit and a neurologist should be contacted immediately.
authors.affiliation: Cliniques Universitaire Saint-Luc, Université Catholique de Louvain, Brussels, Belgium. vanrijckevorsel@nops.ucl.ac.be
authors.forename: Kenou
authors.initials: K
authors.lastname: van Rijckevorsel
authors.forename: Paul
authors.initials: P
authors.lastname: Boon
authors.forename: Henri
authors.initials: H
authors.lastname: Hauman
authors.forename: Benjamin
authors.initials: B
authors.lastname: Legros
authors.forename: Michel
authors.initials: M
authors.lastname: Ossemanns
authors.forename: Bernard
authors.initials: B
authors.lastname: Sadzot
authors.forename: Eric
authors.initials: E
authors.lastname: Schmedding
authors.forename: Michel
authors.initials: M
authors.lastname: van Zandijcke
mesh_terms: D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use; D001530:Belgium; D002986:Clinical Trials as Topic; D006801:Humans; D013226:Status Epilepticus / Q000175:diagnosis* / Q000188:drug therapy*
chemical_list: D000927:Anticonvulsants